New Pills for Poor People ? Empirical Evidence after GATT

  title={New Pills for Poor People ? Empirical Evidence after GATT},
  author={Jean Olson Lanjouw and Iain M. Cockburn},
Ð The protection of pharmaceutical innovations is being dramatically extended as much of the developing world introduces patent protection for new drug products. This change in intellectual property rights may lead to more research on drugs to address developing country needs. We use new survey data from India, the results of interviews, and measures of research and development (R&D) constructed from a variety of statistical sources to determine trends in the allocation of research to products… CONTINUE READING

From This Paper

Figures, tables, and topics from this paper.


Publications citing this paper.
Showing 1-10 of 39 extracted citations

National, Sectoral and Technological Innovation Systems: The Case of Taiwan's Pharmaceutical Industry

2017 Portland International Conference on Management of Engineering and Technology (PICMET) • 2017
View 2 Excerpts


Publications referenced by this paper.
Showing 1-10 of 17 references

CVI Forum No

Children's Vaccine Initiative
16. Geneva. • 1998
View 3 Excerpts
Highly Influenced

Do patents matter?: Empirical evidence after GATT

J. O. Lanjouw, I. Cockburn
View 1 Excerpt

A sleeping storm

View 2 Excerpts

The e€ects of patent

R. html. Rozek, R. Berkowitz
View 1 Excerpt

The race for new drugs hots up

P. Hari
BusinessWorld 7±21 July, 70±73. • 1998
View 1 Excerpt

America's vital interest in global health: protecting our people, enhancing our economy, and advancing our international interest

Institute of Medicine
Washington, DC: National Academy Press. • 1997
View 2 Excerpts

Perspective of the emerging technology company on intellectual property rights and global vaccine supply, AVIRON

T. J. Dunn
CVI/Rockefeller Foundation meeting `The Global Supply of New Vaccines', 3±7 February. • 1997
View 1 Excerpt

Similar Papers

Loading similar papers…